NEUROPACE, INC. Research and Development Arrangement with Federal Government, Costs Incurred, Net
NEUROPACE, INC. (NPCE) reported Research and Development Arrangement with Federal Government, Costs Incurred, Net of $57.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet · last filed 2021-11-10
- 2021-09-30: Research and Development Arrangement with Federal Government, Costs Incurred, Net 9 month $57.00K.
| Period end | Research and Development Arrangement with Federal Government, Costs Incurred, Net 9 month |
|---|---|
| 2021-09-30 | $57.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |